Skip to main content

Table 4 In vitro antifungal susceptibilities of 43 clinical C. africana isolates as determined by the Clinical and Laboratory Standards Institute (CLSI) method

From: Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis

Candida species   AmB FLU NYS TEB AFG CFG MFG
C. africana
DST 182 (14)
Range
GM
MIC90
0.030–0.250
0.052
0.125
0.250–8.000
1.166
4.000
0.125–4.000
0.734
4.000
8.000–256.000
47.031
128.000
0.008–0.030
0.015
0.015
0.125–0.500
0.396
0.500
0.015–0.500
0.056
0.125
C. africana
DST 782
(22)
Range
GM
MIC90
0.030–1.000
0.064
0.250
0.125–2.000
0.567
2.000
0.125–8.000
0.707
4.000
4.000–256.000
21.008
128.000
0.008–2.000
0.013
0.015
0.005–0.500
0.208
0.500
0.015–0.125
0.026
0.125
C. africana
DST 3142
(7)
Range
GM
MIC90
0.030–0.125
0.061
0.125
0.125–2.000
0.410
1.000
0.250–4.000
0.371
0.250
4.000–128.000
28.983
64.000
0.008–0.015
0.010
0.015
0.005–0.500
0.192
0.500
0.015–0.125
0.030
0.125
Sub-total
(43)
Range
GM
MIC90
0.030–1.000
0.060
0.125
0.125–8.000
0.633
2.000
0.125–8.000
0.633
4.000
4.000–256.000
26.979
128.000
0.008–2.000
0.013
0.015
0.005–0.500
0.239
0.500
0.015–0.500
0.032
0.125
C. albicans ATCC90028 (5) Range
GM
MIC90
1.000
0.375
1.000
0.500–1.000
0.250
1.000
0.250–0.500
0.435
0.500
64.000–256.000
190.74
256.00
0.008–0.015
0.009
0.015
0.250
0.250
0.250
0.008–0.015
0.009
0.015
  1. AmB Amphotericin B, FLU Flucytosine, NYS Nystatin, TEB Terbinafine, AFG Anidulafungin, CFG Caspofungin, MFG Micafungin